Why Eli Lilly Stock Sank 18% This Week

Eli Lilly (LLY) shares declined 18% this week, despite the company reporting robust second-quarter results with revenue up 38% to $15.5 billion and net income up 91% to $5.56 billion, primarily driven by strong growth in its weight-loss drugs Mounjaro (+68%) and Zepbound (+172%). The stock's downturn was attributed to investor apprehension regarding potential pharmaceutical tariffs and disappointing trial data showing high dropout rates for its pipeline obesity drug, orfoglipron, raising concerns about future growth drivers. While down 35% from its peak, LLY still trades at a forward P/E of 28, maintaining a premium valuation.

Analysis

Eli Lilly (LLY) shares experienced a significant 18% weekly decline, placing the stock 35% below its all-time high, despite the company reporting exceptionally strong second-quarter results. Revenue surged 38% year-over-year to $15.5 billion and net income grew 91% to $5.56 billion, fueled by its blockbuster weight-loss drugs Mounjaro and Zepbound, which saw revenue growth of 68% and 172% respectively. The market's negative reaction, however, was driven by forward-looking concerns rather than current performance. Investors are primarily focused on two key risks: the uncertainty surrounding potential US pharmaceutical tariffs which could escalate operating costs, and disappointing clinical trial data for orfoglipron, a pipeline obesity drug, which showed high dropout rates and raised concerns about the company's future growth drivers beyond its current portfolio. Despite the stock's correction, its valuation remains at a premium, with a forward price-to-earnings ratio of 28 based on its 2024 EPS guidance of over $20, reflecting a conflict between stellar current fundamentals and mounting future uncertainties.

Key Decisions for Investors

• Investors may view the significant stock pullback as an opportune moment to gain exposure to LLY's robust earnings growth, which saw a 38% year-over-year revenue increase, betting that the market has over-penalized the stock for future uncertainties.
• It is critical to monitor for any concrete news regarding US pharmaceutical tariffs and further clinical data on the orfoglipron pipeline, as these two factors have been identified as the primary drivers of the recent negative sentiment.
• Even after an 18% weekly decline, the forward P/E of 28 indicates a premium valuation, so investors must weigh whether the sustained hyper-growth from Mounjaro and Zepbound is sufficient to justify this multiple against emerging pipeline risks.